DK2849782T3 - Bacteriophag lysin og antibiotiske sammensætninger imod gram-positive bakterier - Google Patents

Bacteriophag lysin og antibiotiske sammensætninger imod gram-positive bakterier Download PDF

Info

Publication number
DK2849782T3
DK2849782T3 DK13787128.1T DK13787128T DK2849782T3 DK 2849782 T3 DK2849782 T3 DK 2849782T3 DK 13787128 T DK13787128 T DK 13787128T DK 2849782 T3 DK2849782 T3 DK 2849782T3
Authority
DK
Denmark
Prior art keywords
positive bacteria
against gram
compositions against
antibiotic compositions
bacteriophage lysine
Prior art date
Application number
DK13787128.1T
Other languages
English (en)
Inventor
Raymond Schuch
Robert C Nowinski
Michael Wittekind
Brent Schneider
Han Lee
Original Assignee
Contrafect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contrafect Corp filed Critical Contrafect Corp
Application granted granted Critical
Publication of DK2849782T3 publication Critical patent/DK2849782T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Paints Or Removers (AREA)
DK13787128.1T 2012-05-09 2013-05-09 Bacteriophag lysin og antibiotiske sammensætninger imod gram-positive bakterier DK2849782T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261644944P 2012-05-09 2012-05-09
US201261737239P 2012-12-14 2012-12-14
PCT/US2013/040329 WO2013170015A1 (en) 2012-05-09 2013-05-09 Bacteriophage lysin and antibiotic combinations against gram positive bacteria

Publications (1)

Publication Number Publication Date
DK2849782T3 true DK2849782T3 (da) 2020-06-22

Family

ID=49551273

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13787128.1T DK2849782T3 (da) 2012-05-09 2013-05-09 Bacteriophag lysin og antibiotiske sammensætninger imod gram-positive bakterier

Country Status (16)

Country Link
US (5) US10813983B2 (da)
EP (2) EP3685851A1 (da)
JP (4) JP6608697B2 (da)
KR (3) KR20210121313A (da)
CN (1) CN104736172A (da)
AU (3) AU2013259512B2 (da)
BR (1) BR112014027842A2 (da)
CA (1) CA2872902A1 (da)
DK (1) DK2849782T3 (da)
ES (1) ES2784136T3 (da)
HK (2) HK1208799A1 (da)
IL (3) IL308477A (da)
IN (1) IN2014MN02437A (da)
MX (2) MX2014013586A (da)
RU (2) RU2018121290A (da)
WO (1) WO2013170015A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2735103C2 (ru) 2012-05-09 2020-10-28 Контрафект Корпорейшн Предотвращение, разрушение и обработка биопленки лизином бактериофага
IL308477A (en) 2012-05-09 2024-01-01 Contrafect Corp Combinations of bacteriophage lysine and antibiotics against gram-positive bacteria
GB2543453A (en) 2014-06-26 2017-04-19 Univ Rockefeller Acinetobacter lysins
KR20170132201A (ko) * 2015-03-12 2017-12-01 마이크레오스 휴먼 헬스 비.브이. 세균 감염의 치료를 위한 살세균제와 라이소좀향성 알칼리화제와의 조합물
AU2016324307B2 (en) * 2015-09-17 2021-10-21 Contrafect Corporation Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
DK3454888T3 (da) * 2016-05-12 2021-04-26 Contrafect Corp Bouillon-mikrofortyndingsfremgangsmåde til evaluering og bestemmelse af minimal inhibitorisk koncentration for antibakterielle polypeptider
EP3641753B1 (en) 2017-06-19 2022-09-21 Syddansk Universitet Bacitracin and/or daptomycin combined with cannabidiol for treatment of bacterial infections
EP3651739A4 (en) * 2017-07-10 2021-04-07 Contrafect Corporation BLOOD COMPONENT POTENTIALIZATION OF LYTIC PROTEIN ANTIBACTERIAL ACTIVITY AND RELATED METHODS AND USES
JP2021513865A (ja) * 2018-02-26 2021-06-03 コントラフェクト コーポレイション 修飾ＰｌｙＳｓ２溶解素及びその使用
BR112020026267A2 (pt) * 2018-06-22 2021-04-06 Contrafect Corporation Lisinas e seus derivados resensibilizam novamente staphylococcus aureus e bactérias gram-positivas aos antibióticos
CN109668873B (zh) * 2018-12-05 2021-03-16 山东恒业生物技术有限公司 一种活载体疫苗活性检测装置及其使用方法
MX2021009398A (es) * 2019-02-05 2021-11-17 Elanco Us Inc Composiciones probioticas que comprenden cepas de lactobacillus reuteri y metodos de uso.
CA3134154A1 (en) * 2019-03-22 2020-10-01 Contrafect Corporation Method of treating infective endocarditis
KR20210151188A (ko) * 2019-04-11 2021-12-13 콘트라펙트 코포레이션 뼈 및 관절 감염증의 치료 및 예방 방법
WO2021127452A1 (en) * 2019-12-19 2021-06-24 Georgia State University Research Foundation, Inc. Compounds for the treatment of bacterial infections and potentiation of antibiotics
RU2755817C1 (ru) * 2020-07-22 2021-09-21 Федеральное Государственное бюджетное научное учреждение "Федеральный научный центр биологических систем и агротехнологий российской академии наук" Способ снижения грамположительной микрофлоры в кишечнике птицы
KR102528412B1 (ko) * 2020-09-08 2023-05-04 클립스비엔씨 주식회사 신규한 포도상구균 감염 질환의 예방 또는 치료용 조성물
WO2022261360A1 (en) * 2021-06-09 2022-12-15 Contrafect Corporation Plyss2 lysins and variants thereof for use against multidrug resistant gram-positive bacteria
CN115105491B (zh) * 2022-07-08 2023-12-22 东北农业大学 丝氨酸在制备抑制猪链球菌药物中的用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2837846B2 (ja) 1986-10-08 1998-12-16 バーンスタイン，デビッド グループａ連鎖球菌抗原を露出させる方法およびグループａ連鎖球菌を同定するための改善された診断試験
CA1315229C (en) 1987-06-10 1993-03-30 Patrick J. Baker Chromatographic purification process
US6121036A (en) * 1996-04-15 2000-09-19 Ghanbari; Hossein A. Compositions containing bacteriophages and methods of using bacteriophages to treat infections
US6248324B1 (en) 1997-10-31 2001-06-19 Vincent Fischetti Bacterial phage associated lysing enzymes for treating dermatological infections
US6264945B1 (en) 1997-10-31 2001-07-24 Vincent A Fischetti Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
US6254866B1 (en) 1997-10-31 2001-07-03 New Horizons Diagnostics Corporation Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract
US20060292135A1 (en) 1997-10-31 2006-12-28 Lawrence Loomis Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl
US5997862A (en) 1997-10-31 1999-12-07 New Horizons Diagnostics Corporation Therapeutic treatment of group A streptococcal infections
EP1162994A4 (en) 1999-02-25 2004-12-29 New Horizons Diagnostics Inc COMPOSITION FOR THE PROPHYLACTIC AND THERAPEUTIC TREATMENT OF STREPTOCOCCAL INFECTIONS
US6056955A (en) 1999-09-14 2000-05-02 Fischetti; Vincent Topical treatment of streptococcal infections
US6444813B2 (en) 2000-02-02 2002-09-03 Pharmacia & Upjohn Company Linezolid-crystal form II
EP1501925A4 (en) 2002-05-17 2006-10-25 New Horizons Diagnostics Corp IDENTIFICATION OF A PHAGEN-ASSOCIATED LYTICAL ENZYME FOR THE FAST AND SPECIFIC DETECTION AND BUTTERFLY OF BACILLUS ANTHRACIS
US7569223B2 (en) 2004-03-22 2009-08-04 The Rockefeller University Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions
WO2005089527A2 (en) * 2004-03-24 2005-09-29 The Rockefeller University Lytic enzymes and spore surface antigen for detection and treatment of bacillus anthracis bacteria and spores
US8389469B2 (en) 2005-06-06 2013-03-05 The Rockefeller University Bacteriophage lysins for Bacillus anthracis
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
DE602006018746D1 (de) 2005-08-24 2011-01-20 Univ Rockefeller Ply-gbs-lysinmutanten
US20090053149A1 (en) 2007-08-24 2009-02-26 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Surfactant-based antimicrobial solution for inhalation
US8840900B2 (en) * 2008-07-03 2014-09-23 The Rockefeller University Chimeric bacteriophage lysin with activity against Staphylococci bacteria
KR101016918B1 (ko) 2009-01-08 2011-02-25 주식회사 인트론바이오테크놀로지 박테리아 특이적 넓은 항균 활성을 갖는 신규한 리신 단백질
US8951532B2 (en) 2010-01-25 2015-02-10 Alere Scarborough, Inc. A25 bacteriophage lysin
WO2012145530A2 (en) * 2011-04-20 2012-10-26 Visa International Service Association Managing electronic tokens in a transaction processing system
EP2699689A4 (en) 2011-04-21 2014-12-17 Univ Utrecht Holding Bv LYSINES OF BACTERIOPHAGES OF STREPTOCOCCUS FOR THE TREATMENT OF GRAM POSITIVE BACTERIA IN PET ANIMALS AND IN LIVESTOCK
EP2699253B1 (en) * 2011-04-21 2018-03-28 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
WO2012145693A1 (en) 2011-04-22 2012-10-26 Rks Design, Inc. Instrument retention assembly
WO2012146738A1 (en) 2011-04-27 2012-11-01 Lysando Holding Ag New antimicrobial agents
IL308477A (en) 2012-05-09 2024-01-01 Contrafect Corp Combinations of bacteriophage lysine and antibiotics against gram-positive bacteria
RU2735103C2 (ru) 2012-05-09 2020-10-28 Контрафект Корпорейшн Предотвращение, разрушение и обработка биопленки лизином бактериофага

Also Published As

Publication number Publication date
RU2018121290A (ru) 2019-03-06
CN104736172A (zh) 2015-06-24
US9889181B2 (en) 2018-02-13
US20210128696A1 (en) 2021-05-06
ES2784136T3 (es) 2020-09-22
IN2014MN02437A (da) 2015-07-10
MX2014013586A (es) 2015-06-05
KR102310387B1 (ko) 2021-10-13
MX2021011843A (es) 2021-10-22
JP2018138045A (ja) 2018-09-06
US20210008175A1 (en) 2021-01-14
AU2018202845A1 (en) 2018-05-10
RU2659208C2 (ru) 2018-06-28
HK1208799A1 (en) 2016-03-18
RU2014149351A (ru) 2016-07-10
IL235527A0 (en) 2015-01-29
US20130302306A1 (en) 2013-11-14
EP3685851A1 (en) 2020-07-29
JP2020054370A (ja) 2020-04-09
CA2872902A1 (en) 2013-11-14
WO2013170015A1 (en) 2013-11-14
AU2013259512B2 (en) 2018-01-25
KR20230113404A (ko) 2023-07-28
IL308477A (en) 2024-01-01
EP2849782A4 (en) 2016-01-20
EP2849782B1 (en) 2020-03-18
AU2018202845B2 (en) 2020-06-18
KR20150035587A (ko) 2015-04-06
US20180221456A1 (en) 2018-08-09
IL274832A (en) 2020-07-30
JP6608697B2 (ja) 2019-11-20
AU2020233683A1 (en) 2020-10-08
HK1211484A1 (en) 2016-05-27
US20150290299A1 (en) 2015-10-15
JP2015523964A (ja) 2015-08-20
KR20210121313A (ko) 2021-10-07
IL235527B2 (en) 2023-10-01
EP2849782A1 (en) 2015-03-25
BR112014027842A2 (pt) 2017-08-08
IL235527B1 (en) 2023-06-01
JP2022058682A (ja) 2022-04-12
US10813983B2 (en) 2020-10-27
AU2013259512A1 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
DK2849782T3 (da) Bacteriophag lysin og antibiotiske sammensætninger imod gram-positive bakterier
DK3360558T3 (da) Sammensætninger omfattende bakteriestammer
DK3628161T3 (da) Synergistiske bakterielle sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
DK3369425T3 (da) Sammensætninger omfattende bakteriestammer
DK3650033T3 (da) Sammensætninger omfattende bakteriestammer
HK1207002A1 (en) Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections
DK3346008T3 (da) Rekombinante mikroorganismer og anvendelser deraf
ES2898695T8 (es) Derivados de benzoxaborol para el tratamiento de infecciones bacterianas
FR2997014B1 (fr) Composition sterile dermo-injectable
DK2961835T3 (da) Ny bakteriophag og antibakteriel sammensætning omfattende samme
BR112015009718A2 (pt) composição de matéria e artigo.
EP2761029A4 (en) NOVEL BACTERIOPHAGE AND ANTIBACTERIAL COMPOSITION THEREWITH
EP2961832A4 (en) NOVEL BACTERIOPHAGE AND ANTIBACTERIAL COMPOSITION THEREWITH
DK2861573T3 (da) Oxathiazin-derivater som antibakterielle og anticancer-stoffer
EP2961833A4 (en) NOVEL BACTERIOPHAGE AND ANTIBACTERIAL COMPOSITION COMPRISING SAME
BR112014006883A2 (pt) bactéria gram-positiva modificada e usos da mesma
EP2995200A4 (en) Sterilization composition with synergism
DK2547361T3 (da) Bakterielle vaccinekomponenter fra staphylococcus aureus og anvendelser deraf
ZA201503474B (en) Compositions and methods for treating bacterial infections
HK1207981A1 (en) Methods of treating and preventing staphylococcus aureus infections and associated conditions
EP2969003A4 (en) METHOD AND COMPOSITIONS FOR BACTERIAL INFECTIONS
EP2844258A4 (en) METHOD AND COMPOSITIONS FOR TREATING BACTERIAL INFECTIONS
HK1204947A1 (en) Sterilized composition
EP2916653A4 (en) ANTIBIOTIC METHODS AND ANTIBIOTIC COMPOSITIONS FOR BACTERIAL INFECTIONS
IL236713B (en) Antibiotic preparations for administration by injection and methods of using them